Related Experiment Video
Updated: Jun 12, 2026
05:00
Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms
Published on: March 3, 2021
Effect of risperidone on acute methamphetamine-induced hyperthermia in rats
Katsutoshi Shioda1, Koichi Nisijima, Tatsuki Yoshino
1Department of Psychiatry, Jichi Medical University, Tochigi, Japan. kazs@jichi.ac.jp
Drug and Alcohol Dependence
|June 15, 2010
Summary
Risperidone effectively reduced methamphetamine (METH)-induced hyperthermia by blocking dopamine-1 and serotonin-2A receptors. This study suggests risperidone as a potential treatment for METH-related hyperthermia.
Area of Science:
- Neuropharmacology
- Toxicology
Background:
- Methamphetamine (METH) abuse is a global issue with increasing fatalities from METH-induced hyperthermia.
- No established treatment currently exists for METH-induced hyperthermia.
Purpose of the Study:
- To investigate the efficacy of risperidone in mitigating acute METH-induced hyperthermia.
- To elucidate the underlying mechanisms of risperidone's action on METH-induced hyperthermia.
Main Methods:
- Administered risperidone pre- and post-METH (10 mg/kg) in a dose-dependent manner.
- Utilized receptor blockers (D1, 5-HT2A, D2, 5-HT1A, 5-HT2B/2C, 5-HT2C) to identify key receptors.
- Conducted microdialysis in rats to measure neurotransmitter and nitric oxide metabolite levels in the anterior hypothalamus.
Main Results:
- Risperidone significantly suppressed METH-induced hyperthermia in a dose-dependent manner.
- The effect was mediated through the blockade of dopamine-1 (DA(1)) and serotonin-2A (5-HT(2A)) receptors.
- METH increased hypothalamic levels of dopamine (DA), serotonin (5-HT), glutamate, and nitric oxide (NO) metabolites (NOx), which were attenuated by risperidone pretreatment.
Conclusions:
- Risperidone demonstrates potential as an effective therapeutic agent for human METH-induced hyperthermia.
- METH impacts multiple neurotransmitter systems, including dopaminergic, serotonergic, glutamatergic, and nitrergic pathways.
